Ultragenyx Pharmaceutical Inc. filed an 8-K on November 3, 2026, disclosing the October 30, 2026 completion of a $210 million Priority Review Voucher sale and announcing a restructuring plan that includes a workforce reduction of approximately 20% of its employees.

Key Highlights

  • PRV sale closed: Ultragenyx completed the sale of its Rare Pediatric Disease Priority Review Voucher on October 30, 2026, receiving gross proceeds of $210 million.
  • NIH payment required: Pursuant to a patent license agreement with the U.S. Department of Health (NIH) dated December 10, 2018, 20% of the gross proceeds from the PRV sale will be paid to the NIH.
  • PRV origin: The FDA awarded the PRV on August 19, 2026 upon approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, for adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa).
  • Workforce reduction: The company announced a restructuring plan on November 3, 2026, implementing a workforce reduction of approximately 20% of its employees, expected to be substantially completed by the end of 2026.
  • Restructuring charges: The company estimates approximately $25 million in total restructuring and restructuring-related charges, consisting primarily of employee severance payments and other employee-related costs, with substantially all charges expected to be recognized in the fourth quarter of 2026.
  • Q3 2026 results: The company issued a press release on November 3, 2026 announcing its financial results for the three months ended September 30, 2026, furnished as Exhibit 99.1.

Ultragenyx Closes PRV Asset Sale and Announces Restructuring Plan

According to the filing, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) completed the sale of its Rare Pediatric Disease Priority Review Voucher on October 30, 2026, under the terms of an asset purchase agreement dated October 6, 2026. The company disclosed that it received gross proceeds of $210 million from the buyer at closing. Under a patent license agreement with the NIH dated December 10, 2018, the company is obligated to pay 20% of those gross proceeds to the NIH. The PRV Asset Purchase Agreement will be filed in full with the company's Annual Report on Form 10-K for the year ended December 31, 2026, according to the filing.

The filing states that the FDA originally awarded the PRV to Ultragenyx on August 19, 2026, following its approval of GENGLYCOS (pariglasgene brecaparvovec-opnr), also known as DTX401, indicated for adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). The PRV sale is described as "previously disclosed" in the filing.

Separately, the company disclosed a restructuring plan on November 3, 2026, which includes a reduction in force of approximately 20% of its employees, communicated to employees on the same date. The company estimates total restructuring and restructuring-related charges of approximately $25 million, consisting primarily of employee severance payments and other employee-related costs. The filing notes that "substantially all" of these charges are anticipated to be recognized during the fourth quarter of 2026, with cash payments generally expected over the same period. The filing cautions that restructuring charges and timing "are subject to a number of estimates and assumptions, and actual results may differ materially."

What Was Disclosed

Ultragenyx disclosed the October 30, 2026 completion of its $210 million PRV sale with a 20% NIH payment obligation, the launch of a restructuring plan including a approximately 20% workforce reduction, and estimated restructuring charges of approximately $25 million, primarily in Q4 2026.